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αvβ3 integrinOver the last years Gallium-68 (68Ga) has received tremendous attention for labeling of radiopharmaceuticals for
positron emission tomography (PET). 68Ga labeling of biomolecules is currently based on bifunctional chelators
containing aminocarboxylates (mainly DOTA and NOTA). We have recently shown that cyclic peptide
siderophores have very good complexing properties for 68Ga resulting in high speciﬁc activities and excellent
metabolic stabilities, in particular triacetylfusarinine-C (TAFC).Wepostulated, that, starting from its deacetylated
form (Fusarinine-C (FSC)) trimeric bioconjugates are directly accessible to developnovel targeting peptide based
68Ga labeled radiopharmaceuticals. As proof of principle we report on the synthesis and 68Ga-radiolabeling of a
trimeric FSC-RGD conjugate, [68Ga]FSC-(RGD)3, targeting αvβ3 integrin, which is highly expressed during
tumor-induced angiogenesis.
Synthesis of the RGD peptidewas carried out applying solid phase peptide synthesis (SPPS), followed by the cou-
pling to the siderophore [Fe]FSC via in situ activation using HATU/HOAt and DIPEA. Subsequent demetalation
allowed radiolabeling of FSC-(RGD)3 with 68Ga. The radiolabeling procedure was optimized regarding peptide
amount, reaction time, temperature as well buffer systems. For in vitro evaluation partition coefﬁcient, protein
binding, serum stability, αvβ3 integrin binding afﬁnity, and tumor cell uptake were determined. For in vitro
tests as well as for the biodistribution studies αvβ3 positive human melanoma M21 and αvβ3 negative M21-L
cells were used.
[68Ga]FSC-(RGD)3was preparedwith high radiochemical yield (N98%). Distribution coefﬁcientwas−3.6 reveal-
ing a hydrophilic character, and an IC50 value of 1.8 ± 0.6 nMwas determined indicating a high binding afﬁnity
for αvβ3 integrin. [68Ga]FSC-(RGD)3 was stable in PBS (pH 7.4), FeCl3- and DTPA-solution as well as in fresh
human serum at 37 °C for 2 hours. Biodistribution assay conﬁrmed the receptor speciﬁc uptake found in vitro.
Uptake in the αvβ3 positive tumor was 4.3% ID/g 60 min p.i. which was 3-fold higher than the monomeric
[68Ga]NODAGA-RGD. Tumor to blood ratio of approx. 8 and tumor to muscle ratio of approx. 7 were observed.
[68Ga]FSC-(RGD)3 serves as an example for the feasibility of a novel class of bifunctional chelators based on cyclic
peptide siderophores and shows excellent targeting properties for αvβ3 integrin in vivo for imaging tumor-
induced neovascularization.uklearmedizin, Medizinische
, Austria. Tel.: +43 512 504
toforo).
 license.© 2014 Elsevier Inc. Open access under CC BY license.1. Introduction
With the increasing availability of 68Ge/68Ga generators, 68Ga-labeled
radiopharmaceuticals, especially based on peptides, are coming into the
focus of research interest in the ﬁeld of radiopharmaceutical sciences [1].
The advantages lie in the easy access of a PET radionuclide without theneed of an in-house cyclotron and the straightforward labeling strategies
which are optimal for synthesis automation. The most widely applied
chelating systems for a variety of radiometals, including 68Ga, is
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
Whereas for somatostatin analogues 68Ga-labeled DOTA-conjugates re-
vealed superior properties regarding pharmacokinetics and receptor af-
ﬁnity in comparison to other radiometals such as 111In [2], for other
peptides imaging properties of the 68Ga labeled construct were inferior
to other radiometals.(e.g. [3]).
Even though the ﬁeld of 68Ga radiopharmaceuticals is rapidly
expanding [4], the number of alternatives to DOTA for conjugation to
biomolecules and subsequent 68Ga-labeling is still limited, and novel
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68Ga-based radiopharmaceuticals.
Siderophores are low molecular-mass chelators with very high
afﬁnity for ferric ions which are utilized by bacteria, fungi, and plants
for iron acquisition and storage [5]. Recently we demonstrated that
68Ga-labeled peptide siderophores, in particular triacetylfusarinine-C
(TAFC), are potential agents for early imaging of invasive pulmonary as-
pergillosis (IPA) due to their high speciﬁc uptake inAspergillus fumigatus
(A.f.) [6,7]. TAFC, a representative of the class of hydroxamate
siderophores, binds 68Ga with high afﬁnity at room temperature (RT)
within minutes achieving very high speciﬁc activities. It is composed
of three N5-hydroxy-L-ornithine and three anhydromevalonic acid
groups (for structure see Fig. 1) forming hexacoordinate Fe3+ and
Ga3+ complexes in a tris-bidentate form involving the three
hydroxamate functions of the molecule, respectively.
We were interested whether such cyclic siderophores could be used
as a basis for preparing targeted bioconjugates for 68Ga labeling. The
siderophore fusarinine-C (FSC) is the deacetylated form of TAFC. We
postulated that the three primary amines of FSC could be used for con-
jugation to biomolecules such as RGD peptides. Whereas [68Ga]TAFC
was extremely stable in serum showing no sign of degradation and
even no release of 68Ga when challenged with FeCl3- or DTPA-
solution, [68Ga]FSC released up to 20% of complexed activity [8]. Based
on these data it was conceivable that acylation as well as alkylation of
the amines of FSC may have a stabilizing effect on the siderophore and
could be used for conjugation of targeting sequences.
To prove this hypothesis, we initially attempted to prepare a simple
trimeric conjugate using acetyl prolin to test various strategies for con-
jugation of peptidic structures to FSC. This was followed by conjugation
of an RGD peptide as a well established targeting sequence. A great va-
riety of different radiolabeled RGD-peptides have been described la-
beled with halogens as well as with various radiometals (for reviewSubstituent R
[68Ga]FSC H
[68Ga]TAFC COCH3
[68Ga]FSC-(AcPro)3 N-acetylpyrrolidine-
[68Ga]FSC-(RGD)3 cyclo(-Arg-Gly-Asp
Fig. 1. Proposed structures of [68Ga]FSC, [68Ga]TAFsee [9,10]) and therefore cyclic RGD peptides can serve as an excellent
model for targeting applications. They bind the αvβ3 integrin found on
activated endothelial cells during tumor-induced angiogenesis and
also being highly expressed on various tumor types, e.g. melanoma,
glioblastoma, pancreatic-, and cervical cancer [11]. In this study we re-
port on the feasibility of preparing a trimeric FSC-RGD conjugate for
68Ga labeling and the initial comparison of its biological properties
with the established monomeric [68Ga]NODAGA-RGD [12].
2. Materials and methods
2.1. General
All chemicals were used as supplied without further puriﬁcation.
9-Fluorenylmethoxycarbonyl (Fmoc) protected amino acids were pur-
chased from Novabiochem (La Jolla, CA, USA). The solid support
tritylchloride polystyrene resin (TCP resin) was obtained from
PepChem (Reutlingen, Germany). Coupling reagents 1-Hydroxy-7-
azabenzotriazole (HOAt) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyl uroniumhexaﬂuorophosphate (HATU) were purchased
from GenScript Corporation (Piscataway, NJ, USA). All other chemicals
were obtained from VWR International GmbH (Vienna, Austria) or
Sigma-Aldrich Handels GmbH (Vienna, Austria). Human M21 and
M21-Lmelanoma cells were a kind gift fromD. A. Cheresh, Departments
of Immunology and Vascular Biology, The Scripps Research Institute, La
Jolla, CA, USA.
Reversed-phase high performance liquid chromatography (RP-
HPLC) analysis was performed with an UltiMate 3000 RS HPLC pump,
an UltiMate 3000 RS Column compartment (column oven temperature
was set at 25 °C), an UltiMate 3000 Variable Wavelength detector
(Dionex, Gemering, Germany), and a Bioscan radiometric detector
(Bioscan, Washington DC, USA). A Vydac 218 TP5215, 150 × 3.0 mm2-carbonyl
-DPhe-Lys(Succ)-)
C, [68Ga]FSC-(Ac-Pro)3 and [68Ga]FSC-(RGD)3.
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tion at 220 nmwere employedwith the following acetonitrile (CH3CN)/
H2O/0.1% TFA gradients: 0–2.0 min 0% CH3CN, 2.0–16.0 min 0–40%
CH3CN (gradient A); 0–2.0 min 30% CH3CN, 2.0–18.0 min 30–80%
CH3CN (gradient B); 0–2.0 min 0% CH3CN, 2.0–18.0 min 0–80% CH3CN
(gradient C); and 0–0.5 min 0% CH3CN, 0.5–7.0 min 0–55% CH3CN
(gradient D).
Cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys(Succ)-) was isolated via
preparative RP-HPLC using a Gilson 322 HPLC pump with Gilson UV/
VIS-155 detector (Gilson International B.V., Limburg, Germany) and a
MultoHigh 100 RP 18 5 μm,250×10mmcolumn(CS–Chromatographie
Service GmbH, Langerwehe, Germany). Flow rate was 5.0 ml/min. The
used CH3CN/H2O/0.1% TFA gradient was as follows: 0–1.0 min 30%
CH3CN, 1.0–21.0 min 30–80% CH3CN (gradient E). Puriﬁcation of
Fusarinine-C was carried out via preparative RP-HPLC using a P580
HPLC pump (Dionex, Gemering, Germany), a GynkotekWavelength de-
tector (Gynkotek, Gemering, Germany), and a Seibersdorf Nucleosil
120-10 C18, 250 × 8 mm column (Austrian Institute of Technology,
Seibersdorf, Austria) with a ﬂow rate of 5 ml/min and a gradient with
following speciﬁcations: 0–1.0 min 5% CH3CN, 1.0–14.0 min 5–40%
CH3CN (gradient F). [Fe]FSC-(RGD)3 as well as FSC-(RGD)3 were puri-
ﬁed by semipreparative RP-HPLC employing the same system compo-
nents as described before for the siderophore but using instead a
Bischoff Nucleosil 120-5-C18 5 μm, 250 × 4.6 mm column (Bischoff
Analysentechnik und -geräte GmbH, Leonberg, Germany) with a ﬂow
rate of 1.5 ml/min. The gradient was: 0–1.0 min 0% CH3CN,
1.0–2.0 min 0–25% CH3CN, 2.0–18.0 min 25–35% CH3CN (gradient G).
Matrix-assisted laser desorption/ionization–time of ﬂight–mass
spectrometry (MALDI-TOF-MS) was carried out using α-cyano-4-
hydroxy-cinnamic acid as the matrix and a Bruker Ultraﬂex mass spec-
trometer (Ultraﬂex MALDI TOF-TOF; Bruker Daltonics, Bremen,
Germany). All spectra were recorded by summarizing 600 laser shots,
using a 337 nmnitrogen laser with a pulse of 50 Hz. For data processing
Flex Analysis 2.4 software was used.
The radioactivity of in vitro as well as in vivo samples was measured
using a 2480 Automatic Gamma Counter Wizard2 3″ (Perkin Elmer,
Vienna, Austria).
The 68Ga-generator was purchased from Eckert & Ziegler
Strahlen- und Medizintechnik AG (Berlin, Germany) with a nominal
activity of 1100 MBq and was eluted with 0.1 M HCl solution (Rotem
Industries Ltd., Beer-Sheva, Israel) carrying out the fractionated elution
approach [13].
2.2. Cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys-)
Detailed synthesis procedure is described elsewhere [14]. Brieﬂy, the
linear RGD-peptide was synthesized on a solid support using a
tritylchloride resin (TCP resin) and Fmoc protocols. Protecting groups
were 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for
arginine, tert-butyl (tBu) for aspartic acid, and benzyloxycarbonyl
(Z) for lysine. Cyclization of the peptide was performed in
dimethylformamide (DMF) in the presence of diphenylphosphoryl
azide (DPPA) and sodium hydrogen carbonate (NaHCO3) as solid base.
Subsequent deprotection of the Lysine side chain was carried out
under hydrogen atmosphere in the presence of an activated charcoal
palladium catalyst in N,N-dimethylacetamide (DMA) resulting in cyclo
(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys-).
2.3. Cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys(Succ)-)
To cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys-) (100mg, 0.11mmol)
dissolved in 5 ml DMF, 2 eq of succinic anhydride (22 mg, 0.22 mmol)
were added. The mixture was stirred for 12 h at RT. Subsequently the
solvent was reduced in vacuo and the peptide precipitated by addition
of water. The crude product cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys
(Succ)-) was washed, dried and ﬁnally puriﬁed via preparativeRP-HPLC (gradient E): tR = 15.3 min, yield: 62 mg cyclo(-Arg(Pbf)-
Gly-Asp(OtBu)-DPhe-Lys(Succ)-) (0.06 mmol, 56% of theoretical
yield). RP-HPLC (gradient B): tR = 7.9 min. For liquid chromatography
mass spectrometry (LC-MS) a fritless nanospray column (100 μm ID,
packed to 10 cm with 3 μm C18 material (in-house construction) and
an LTQ ion trap instrument (Thermo Finnigan; San Jose, CA, USA)
equipped with a nanospray source and an UltiMate 3000 HPLC pump
(Dionex, Germering, Germany) were used. ESI-MS: m/z [M + H]+ =
1012.6 [C48H69N13O9S; exact mass: 1011 (calculated)].
2.4. [Fe]Fusarinine-C
Aspergillus fumigatus strain ΔsidG was cultured for 36 h at 37 °C at
200 rpm in Aspergillus minimal medium containing 1% (m/v) glucose
as carbon source, glutamine (20 mM) as nitrogen source, salts, and
trace elements, as described previously by Schrettl et al. [15]. Brieﬂy,
for preparation of iron-deﬁcient media, iron addition was omitted.
Iron-deﬁcient conditions were veriﬁed by detection of extracellular
siderophore production, which is suppressed by iron. Secreted
Fusarinine-C (FSC) was then saturated with iron and puriﬁed from the
culture supernatant using Amberlite™ XAD18 beads (Dow Chemical
Company, Philadelphia, PA, USA) as column matrix. Elution of [Fe]FSC
from the Amberlite XAD column was carried out using methanol. [Fe]
FSC was then additionally puriﬁed via RP-HPLC (gradient F): tR =
8.3 min. MALDI TOF-MS: m/z [M + H]+ = 780.4, [M + Na]+ = 802.4
[C33H51FeN6O12; exact mass: 779 (calculated)].
2.5. Conjugation of [Fe]FSC with N-Acetyl-L-proline
To [Fe]FSC (1.2mg, 1.5 μmol) dissolved in 1mLDMF,N-acetyl-L-pro-
line (2.4mg, 15.4 μmol) in 50 μLwas added. After in situ activation using
HATU/HOAt and adjusting the pH to 9 via DIPEA the solution was
allowed to react at RT for 10 h. Hereon, [Fe]FSC-(N-acetyl-Pro)3 ([Fe]
FSC-(AcPro)3) was precipitated using diethyl ether, washed several
times with diethyl ether and ﬁnally dried in vacuo. RP-HPLC (gradient
A): tR = 12.2 min. MALDI TOF-MS: m/z [M + H]+ = 1197.5
[C54H78FeN9O18; exact mass: 1196 (calculated)].
2.6. FSC-(AcPro)3
[Fe]FSC-(AcPro)3 (0.9 mg) was dissolved in 2 mL of a solution of
disodium ethylenediaminetetraacetic acid (Na2EDTA) in H2O (25 mM,
pH 4). After 12 h reaction time the solution was diluted to 10 ml with
H2O; FSC-(AcPro)3 was puriﬁed via a C18 sep-pak cartridge ﬁxation
and eluted with CH3CN/0.1% TFA. Finally the eluate was evaporated to
dryness and the residue dissolved in H2O (2.5:1 m/v).
2.7. [68Ga]FSC-(AcPro)3
Labeling was carried out using the fractionated elution method. To
50 μg of FSC-(AcPro)3 in 20 μL H2O, 100 μL of activity (approx.
35–50 MBq 68GaCl3 in 0.1 M HCl), and 30 μL sodium acetate solution
(1.1 M) were added. The labeling mixture was allowed to react for
15 min at 70 °C and was used without further puriﬁcation. RP-HPLC:
tR = 12.2 min (gradient A).
2.8. Conjugation of [Fe]FSC and cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys
(Succ)-)
[Fe]FSC (3 mg, 3.9 μmol) and an excess of 5 eq cyclo(-Arg(Pbf)-Gly-
Asp(OtBu)-DPhe-Lys(Succ)-) (19.5 mg, 19.2 μmol) were dissolved in
800 μL DMF. After addition of 7.3 mg HATU (19.2 μmol), 2.6 mg HOAt
(19.2 μmol) and adjustment of the pH to 9 using DIPEA the reaction
mixture was stirred for 72 h at RT. Hereafter, the volume of solvent
was reduced in vacuo, and the conjugate was precipitated using water.
Finally, the precipitate was washed with water and dried to give [Fe]
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red colored solid. The crude product was used for the next synthesis
step without further puriﬁcation. RP-HPLC (gradient B): tR = 14.0 min.
2.9. Deprotection of [Fe]FSC-(cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys
(Succ)-)3
For deprotecting the conjugate [Fe]FSC-(cyclo(-Arg(Pbf)-Gly-Asp
(OtBu)-DPhe-Lys(Succ)-)3 (6.4mg)was dissolved in 1.3mLof a solution
composed of TFA/H2O/triisopropylsilan in a ratio of 38:1:1. The reaction
mixture was allowed to react for 10 h at RT. Subsequently the solvent
was reduced, and crude [Fe]FSC-(RGD)3 was obtained by precipitation
using diethyl ether. Finally the product was dried and puriﬁed via
preparative RP-HPLC (gradient G): tR = 15.2 min, yield: 4.7 mg [Fe]
FSC-(RGD)3.(CF3COOH)3 (1.5 μmol). RP-HPLC (gradient C): tR =
10.0 min. MALDI TOF-MS [M + H]+ = 2836.1 [C126H180FeN33O39;
exact mass: 2835 (calculated)].
2.10. FSC-(RGD)3
Demetalation of the [Fe]FSC-(RGD)3 was accomplished by dis-
solving 1.9 mg (0.6 μmol) of the conjugate in 1 mL of a disodium
ethylenediaminetetraacetic acid (Na2EDTA) solution (25 mM).
After 10 h stirring at RT the solution was concentrated in vacuo, and
FSC-(RGD)3 was directly isolated via preparative RP-HPLC (gradient G):
tR = 15.9 min, yield: 0.7 mg FSC-(RGD)3 (CF3COOH)3 (0.2 μmol, 37% of
theoretical yield). RP-HPLC (gradient C): tR = 10.1 min. MALDI-TOF-MS
[M+ H]+= 2785.0 [C126H183N33O39; exact mass: 2782.3 (calculated)].
2.11. [68Ga]FSC-(RGD)3
Labeling procedure of FSC-(RGD)3 was optimized regarding the
amount of peptide, type of buffer, and reaction time. Details can be
found in Table 1. Overall to 0.5–30 μg FSC-(RGD)3 30 μL sodium acetate
solution (1.1M) and 100 μL 68GaCl3 of themain fraction of the generator
eluate (approx. 35–50 MBq in HCl (0.1 M)) were added. Analysis was
performed using RP-HPLC (gradient D): tR = 6.6 min.
2.12. Distribution coefﬁcient (logD)
To [68Ga]FSC-(RGD)3 (approx. 0.4 MBq in 50 μL, 125 pmol peptide)
diluted in 450 μL phosphor buffered saline (PBS) octanol (500 μL) was
added. Hereafter, the mixture was vortexed for 15 min at 1400 rpm
and centrifuged for 2 min at 2000 rcf. Subsequently, aliquots of the
aqueous and the octanol layer were collected, measured in the gamma
counter, and logD values were calculated (n = 5).Table 1
Optimization of the labeling conditions for FSC-(RGD)3.
Peptide
amount
[μg]
Peptide
amount
[nmol]
A [μL] B [μL] pH Reaction
time [min]
RCY [%] Speciﬁc
activity
[TBq/mmol]
0.5 0.18 30 4.5–5 15 96.0 ± 1.1 214 ± 2.6
2 0.72 30 4.5–5 5 94.5 ± 2.6 53 ± 1.5
2 0.72 30 4.5–5 15 97.2 ± 1.5 54 ± 0.9
2 0.72 20 5 5 95.6 ± 1.7 53 ± 0.9
2 0.72 20 5 15 96.9 ± 0.4 54 ± 0.2
5 1.80 20 3–4 15 94.1 ± 1.5 21 ± 0.7
5 1.80 30 4.5–5 15 98.5 ± 0.7 22 ± 0.1
10 3.59 30 4.5–5 15 99.3 ± 1.3 11 ± 0.1
30 10.78 30 4.5–5 15 99.5 ± 0.8 4 ± 0.03
Optimization reaction time, peptide amount, and buffer systems were modiﬁed.
Activity: 100 μL of 68GaCl3 in 0.1 M HCl (30–50 MBq), reaction at room temperature.
The radiochemical purity was determined by radio-HPLC.
A: 310 mg sodium acetate trihydrate (NaOAc · 3H2O) in 2 mL H2O (1.1 M, pH 8.3).
B: NaHEPES (1 M)/HEPES (1 M) (2:1) (1.0 M) (1.0 M, pH 8.2).2.13. Stability assay
Determination of stability of [68Ga]FSC-(AcPro)3 and [68Ga]FSC-
(RGD)3 was carried out incubating the radiotracers for 30, 60, and
120 min at 37 °C, respectively. Therefore, [68Ga]FSC-(AcPro)3 or [68Ga]
FSC-(RGD)3 was incubated in 2 mL of PBS (approx. 1.5 MBq,
0.4 nmol), FeCl3- (N1000-fold molar excess of iron), DTPA solution
(pH 7.1; N1000-fold molar excess of DTPA) and in 2 mL (approx.
5 MBq, 1.25 nmol) of fresh human serum, respectively. At selected
time points aliquots of PBS-, FeCl3-, or DTPA solution were analyzed di-
rectly via RP-HPLC, while serum aliquots were mixed with 500 μL
CH3CN, vortexed, and centrifuged at 20000 rcf for 2min before analysis.
RP-HPLC analysis applying gradient A was used. Extraction efﬁcacy was
determined by dividing the activity of the supernatant by the total activ-
ity used in this assay.
2.14. Protein binding assay
Protein binding ability for [68Ga]FSC-(RGD)3 was evaluated incubat-
ing the radiotracer for 30, 60, and 120 min at 37 °C in fresh human
serum. Subsequently, the solutions were passed through a size exclu-
sion spin column (MicroSpin™ G-50 columns, GE healthcare, Bucking-
hamshire, UK) via centrifugation at 2000 rcf for 2 min. Protein binding
ability was determined by measuring the activity bound to the column
(non-protein bound) and the activity in the eluate (protein bound) in
a gamma counter.
2.15. Binding afﬁnity for immobilized αvβ3 integrin (IC50 value)
In vitro binding afﬁnities of FSC-(RGD)3 and cyclo(-Arg-Gly-Asp-
DTyr-Val-) (c(RGDyV)) as control were determined by using isolated
αvβ3 integrin (Millipore-Chemicon, Temecula, CA, USA) and 125I labeled
c(RGDyV) as radioligand. The detailed procedure can be found in [16].
Brieﬂy, 96-well plates (Nunc, Thermo Fisher Scientiﬁc, Vienna,
Austria) were coated for 16 hours at 4 °C with the αvβ3 integrin. Subse-
quently, the immobilized receptors were incubated with [125I]c
(RGDyV) and increasing concentrations of the corresponding peptide
ranging from 0.001 to 100 nM. The unbound fraction of radioligand
was washed out, and receptor bound activity was obtained treating
the wells with sodium hydroxide (NaOH) solution (2 M). IC50 values
were determined by ﬁtting the percent inhibition using OriginPro 8.5
software (Northhampton,MA, USA). Three independentmeasurements
were made.
2.16. Internalization assay
M21(αvβ3 positive) andM21-L cells (negative control)were diluted
with RPMI 1640 (Gibco, Invitrogen Corporation, Paisley, UK) containing
1% glutamine (m/v), 1% bovine serum albumin (BSA) (m/v), CaCl2
(1 mM), MgCl2(1 mM), and MnCl2 (10 mM) to a concentration of 2
× 106 cells/mL, and aliquots of 1 mL were transferred to Eppendorf
tubes for incubation for 1 h at 37 °C. After addition of [68Ga]FSC-
(RGD)3 (approx. 1.5 × 106 cpm, 22nM), the cellswere incubated in trip-
licateswith either PBSwith 0.5% BSA (150 μL, total series) orwith 10 μM
c(RGDyV) in PBS/0.5% BSA (150 μL, nonspeciﬁc series) at 37 °C for
90 min. The incubation was stopped via centrifugation, the medium re-
moved, and the cells were rinsed twice with ice-cold TRIS-buffered sa-
line. Subsequently, the cells were incubated in acid wash buffer
(20 mM acetate buffer, pH 4.5) at 37 °C for 15 min. After centrifugation
the cells were washed with acid wash buffer, subsequently lyzed by ad-
dition of 2 M NaOH, and the radioactivity associated with cells was
collected (internalized radioligand fraction). Protein content in the
NaOH fraction was determined by way of spectrophotometry using
Bradford reagent (Sigma, Vienna, Austria). Internalized activity was
determined and expressed as percentage of total activity per
milligram protein.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Retention time [min]
Fig. 2. HPLC radiochromatograms of [68Ga]FSC-(RGD)3: (front/black: radiolabeling solution, middle: stability after 120 min incubation at 37 °C in DTPA solution (blue), FeCl3 solution
(yellow) and (last) fresh human serum (red).
Table 2
Protein binding and stability values after 30, 60, and 120 min incubation at 37 °C.
Incubation time [min] A [%] B [%] C [%] D [%]
30 10.6 99.9 99.3 98.1
60 9.55 99.9 99.1 98.1
120 10.0 99.9 99.2 97.0
A: serum protein binding.
B: stability in fresh human serum.
C: stability in FeCl3 solution.
D: stability DTPA solution.
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Biodistribution studies were conducted in compliance with the
Austrian animal protection laws and with approval of the Austrian Min-
istry of Science (BMWF-66.011/0135-II/10b/2008). For the induction of
tumor xenografts, M21 and M21-L cells were subcutaneously injected
at a concentration of 5 × 106 cells/mouse and were allowed to grow
until tumors reached a volume of 0.3–0.6 cm3. To determine theαvβ3 re-
ceptor speciﬁc uptake Balb/c nu/nu mice (Charles River, Sulzfeld,
Germany) bearing the human melanoma tumor M21 in the right ﬂank
and αvβ3 negative M21-L (as a negative control) in the left ﬂank were
used (n = 4). [68Ga]FSC-(RGD)3 (~1 MBq/animal, ~0.4 μg peptide,
0.14 nmol) was intravenously injected in the tail vein. The animals
were sacriﬁced by cervical dislocation60minpost injection, respectively.
Organs (heart, stomach, spleen, liver, pancreas, kidneys, and intestine),
blood, muscle tissue and tumors were removed and weighted. Activity
uptake of the samples was measured in the gamma counter. Results
were expressed as percentage of injected dose per gram tissue (% ID/g).
3. Results
3.1. Peptide synthesis and coupling to the chelator
N-acetyl-L-proline was coupled straightforward via its carboxylic
function to the amino groups of [Fe]FSC in high yields. After
demetalation, FSC-(AcPro)3 was puriﬁed via sep-pak cartridge for pre-
liminary proof of radiolabeling.
Cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys(Succ)-) could be synthe-
sized in good yield. Assembly of the linear RGD peptide was accom-
plished on solid phase using Fmoc-protocols. Cyclization was carried
out under high dilution conditions and subsequent partial
Z-deprotection under hydrogen atmosphere. In a next step the lysine
side chain was modiﬁed via addition of succinic acid enabling the cou-
pling of the RGD peptide to the primary amino functions of [Fe]FSC.
Amidation of cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys(Succ)-) with
[Fe]FSC was accomplished via in situ activation using HATU/HOAt and
DIPEA (a representative HPLC chromatogram is found in supplementarymaterial Fig. S1). Complete deprotection and subsequent demetalation
of the organometalic complex resulted in an average yield of approx.
40% FSC-(RGD)3. After HPLC puriﬁcation the chemical purity (CP) of
FSC-(RGD)3 amounted to N 95% (see supplementary material Fig. S2).3.2. Radiolabeling
[68Ga]FSC-(AcPro)3 and [68Ga]FSC-(RGD)3 were obtained in radio-
chemical yields (RCY) N 94% comparable to 68Ga-labeling of NODAGA-
RGD. Standard conditions of 30 μg of FSC-(RGD)3 in 30 μL H2O, 100 μL
of 68GaCl3 in 0.1 M HCl and 30 μL sodium acetate solution (1.1 M)
reacting for 15 min were applied for in vitro and in vivo tests and the
radiolabeling solution used without further puriﬁcation.
For optimization of the radiolabeling process of FSC-(RGD)3 different
amounts of peptide (0.5–30 μg), varying time points (5–30min), differ-
ent buffer systems (NaOAc or NaHEPES/HEPES) and buffer amounts
(15–60 μL), as well as different reaction temperatures (RT:70 °C) were
evaluated. Speciﬁc activities (SA) ranged from 4 to 200 TBq/mmol. A se-
lected list of radiolabeling data is presented in Table 1 showing that
0.5 μg (0.18 nmol) of FSC-(RGD)3 was sufﬁcient to be labeled with
68Ga even at RT without further puriﬁcation with an RCP greater than
95% achieving an SA of 200TBq/mmol. Whereas under the conditions
applied a pH of 4.5–5 resulted in a somewhat higher RCP as compared
to pH 3-4, no signiﬁcant differences were found in the buffer type
used (HEPES vs. acetate) or when comparing incubation at RT vs. 70 °C.
ML-12M12
0
1
2
3
4
5
6
7
8
9
10
%
 o
f t
ot
al
 a
ct
iv
ity
 / 
m
g 
pr
ot
ei
n 
[%
 cp
m
/m
g]
 [68Ga]FSC-(RGD)3 (22 nM) 
[68Ga]FSC-(RGD)3 (22 nM) blocked with c(RGDyV) (22 µM)
Fig. 3. Cell uptake studies using humanmelanomaM21 (αvβ3 positive) and M21-L (αvβ3
negative) cells showed a receptor speciﬁc internalization for [68Ga]FSC-(RGD)3 (22 nM);
binding to receptor negative M21-L and after blocking using c(RGDyV) (22 μM)
are negligible.
blo
od
spl
een
pa
nc
rea
s
sto
ma
ch
Int
est
ine
kid
ne
ys
liv
er
he
art
m
us
cle M2
1
M2
1-L
0
1
2
3
4
5
6
%
ID
/g
 [68Ga]FSC-(RGD)
3
 [68Ga]NODAGA-RGD  
Fig. 4. Comparison of biodistribution data of [68Ga]FSC-(RGD)3 with [68Ga]NODAGA-RGD
60min p.i. (from [12]). For the biodistribution study nudemice bearing theαvβ3-positive
human melanoma M21 on the right ﬂank and the negative control tumor M21-L on the
left ﬂank were used.
120 P.A. Knetsch et al. / Nuclear Medicine and Biology 42 (2015) 115–1223.3. In vitro characterization
Distribution coefﬁcient (logD) of [68Ga]FSC-(RGD)3 was −3.6 re-
vealing a hydrophilic character.
Serum protein-bound activity of [68Ga]FSC-(RGD)3 was approx. 10%
of total activity after 30 min incubation in serum, and this value
remained stable for the whole monitoring period.
Both [68Ga]FSC-(AcPro)3 and [68Ga]FSC-(RGD)3 were stable in PBS,
FeCl3, and in DTPA solution as well as in fresh human serum at 37 °C
for 2 h, respectively (Fig. 2). Extraction efﬁciency of [68Ga]FSC-(RGD)3
in serum was approx. 85%. Protein binding and stability data are sum-
marized in Table 2.
Increasing amounts of FSC-(RGD)3 or c(RGDyV) as control success-
fully suppressed the binding of [125I]c(RGDyV) to the immobilized
αvβ3 integrin. IC50 values were 1.8 ± 0.6 nM for FSC-(RGD)3 and
3.2 ± 1.2 nM for c(RGDyV).
By incubating [68Ga]FSC-(RGD)3 (22 nmol) with M21 and M21-L
tumor cells and carrying out corresponding blocking studies (22 μmol c
(RGDyV)) internalization ability of the multimeric RGD peptide was de-
termined (Fig. 3). The internalized activity was 5.3± 0.5% of total activity
per milligram protein [% cpm/mg] forαvβ3 positive M21 cells which was
reduced to approx. 1/25 of the reference activity via addition of c(RGDyV).
In contrast, blocking of M21-L cells just caused a negligible small reduc-
tion of accumulated activity decreasing the uptake from 0.3 to 0.2%
cpm/mg. Furthermore, the remaining internalized activity in the blocked
M21 cells equaled the activity accumulation found for M21-L cells.
3.4. In vivo characterization
Biodistribution and speciﬁc tumor uptake of [68Ga]FSC-(RGD)3 were
determined 60 min postinjection in Balb/c nu/nu mice bearing M21
(αvβ3 positive) as well as M21-L (αvβ3 negative) tumors (n = 4).
Collected data are shown in Fig. 4.
Sixty min postinjection the absolute uptake of [68Ga]FSC-(RGD)3 in
the αvβ3 positive M21 tumor was 4.25 ± 0.64% ID/g, but only 1.13 ±
0.38% ID/g in the contralateral negative M21L tumor, being highly sig-
niﬁcant and conﬁrming the receptor-selective uptake found in vitro. Ac-
tivity concentrations in the different organs ranged from 0.6± 0.1%ID/g
found for muscle tissue to 4.7 ± 0.5%ID/g for kidneys. Apart from that,
activity accumulation in the blood was 0.5 ± 0.2% ID/g resulting in a
tumor to blood ratio of 8.2 and a tumor to muscle ratio of 7.4 (in com-
parison [68Ga]NODAGA-RGD: 11.3 and 6.1, respectively).4. Discussion
FSC as starting material for conjugation of targeting sequences was
obtained from fungal cultures. Siderophores are produced in large
quantities by fungi under iron starvation conditions amounting to up
to 10% of their biomass [17]. This provides easy and straight forward ac-
cess of desferrifusigen and, after addition of Fe(III), of FSC for chemical
modiﬁcations. E.g., isolation andHPLC puriﬁcation froma 200ml culture
resulted in more than 20 mg of FSC in high purity.
Derivatization of FSC's amine functions required a selective protec-
tion strategy for the hydroxamate groups. Initial attempts to react
desferrifusigen, the desferric form of FSC, with HATU/HOAt in DMF
and N-acetyl-Pro-OH failed in regioselective coupling of N-acetyl-Pro-
OH to the aminogroups of desferrifusigen. Therefore the iron containing
peptide siderophorewas used as startingmaterial utilizing the iron che-
lation as protection for the hydroxamate function in analogy to Verel
et al. [18]. They used a temporary blocking of hydroxamate groups via
addition of Fe3+ for derivatizing Desferrioxamine B (DFO), a linear pep-
tide siderophore, for subsequent antibody conjugation and 89Zr-label-
ing. Applying the same approach starting from FSC initially to
synthesize the model compound [Fe]FSC-(AcPro)3 and then corre-
spondingly FSC-(RGD)3 resulted in a high chemical purity as well as in
satisfying overall chemical yields. The straightforward removal of iron
from [Fe]FSC-(AcPro)3 as well as from [Fe]FSC-(RGD)3 in the ﬁnal step
using EDTA at pH 4 can be explained by the phenomenon that
hydroxamate based siderophores show a considerably facilitated re-
lease of iron under acidic conditions [19]. In contrast to that, at neutral
pH both 68Ga-labeled FSC conjugates showed almost no sign of
transchelation in DTPA solution. Moreover, both compounds were
very stable in serum and all challenging solutions during the in vitro
testing which was comparable with [68Ga]NODAGA-RGD, indicating
high stability for in vivo targeting [12].
Radiolabeling of FSC-(RGD)3 using standard protocols also applied
to [68Ga]NODAGA-RGD resulted in a high RCP at RT within minutes at
high speciﬁc activities with little inﬂuence of reaction conditions such
as temperature or buffer type. Without pre-concentration or puriﬁca-
tion of the 68Ga eluate speciﬁc activity of up to 200 TBq/mmol was
reached. Recently, Notni et al. [20] introduced another trimeric RGD
peptide, 68Ga-TRAP-(RGD)3, based on a (1,4,7-triazacyclononane-
1,4,7-tris[methyl(2-carboxyethyl)phosphinic acid]) (TRAP) structure.
This TRAP chelating system forms highly stable complexes with Ga3+
allowing efﬁcient radiolabeling over a wide pH range and a
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without affecting the integrity of the complexation site, concordant
with the concept presented here for FSC conjugation. They report that
speciﬁc activities in the range of 5000 TBq/mmol using 1 GBq of 68Ga
are routinely achievable [21].
It can be expected for FSC based constructs that considerably higher
speciﬁc activities are achievable by further optimization of the
radiolabeling procedure and appropriate eluate post processing
methods [22,23]. Further studies are currently ongoing using a new,
high activity generator aswell as pre-concentration to fully test the spe-
ciﬁc activity limit of FSC-based bioconjugates.
Distribution coefﬁcient (logD) of [68Ga]FSC-(RGD)3was−3.6which
is the same as for the monomeric [68Ga]NODAGA-RGD revealing a very
hydrophilic character. In contrast to that, protein binding was 10%,
which remained stable for the whole monitoring period, as compared
to ﬁve-fold lower values for [68Ga]NODAGA-RGD.
A high binding afﬁnity to the isolated αvβ3 integrin for [68Ga]FSC-
(RGD)3was found. Its IC50 valuewas in the lownanomolar range, signif-
icantly lower as compared to [68Ga]NODAGA-RGD (1.8 vs. 4.7 nM, re-
spectively). This also explains the considerably improved binding to
αvβ3 integrin expressing cells. An approx. 16-fold higher activity
found in the αvβ3-positive cells than in the negative control proved a
receptor-mediatedmechanism. A remarkable enhancement of internal-
ized activity in comparison to [68Ga]NODAGA-RGD or othermonomeric
RGDderivatives [3,16]was observed.Moreover, onlyαvβ3-positive cells
could be blocked via addition of c(RGDyV) leading to 1/25 of total activ-
ity in comparison to M21 cells additionally conﬁrming the receptor-
mediated binding and uptake.
In addition to in vitro tests, receptor-speciﬁcity was conﬁrmed in a
biodistribution study using nudemice bearingM21- andM21-L tumors
showing a four-fold higher uptake in theM21- than in the receptor neg-
ative M21-L tumor 60 min after injection. In this study not the highest
achievable speciﬁc activity of [68Ga]FSC-(RGD)3 was used in order to
provide comparable conditions with previous data of radiolabeled
RGD peptides in the same tumor model using the same mouse strain,
gender and weight. This resulted in a more than threefold higher
in vivo tumor accumulation as compared to [68Ga]NODAGA-RGD (4.3%
vs. 1.3% ID/g). We believe that higher speciﬁc activities will not yield
better targeting properties at least in this model, as it has been shown
that even co-injection of 6mg/kg c(RGDfV) still allowed receptor specif-
ic visualization of M21 [24].
The development of multivalent radiopharmaceuticals presenting
more than one targeting vector has recently attracted considerable in-
terest. It is assumed that these multimeric compounds on the one
hand improve the receptor afﬁnity due to the avidity effect and on the
other handprolong the retention in the target due to increased apparent
tracer concentrationwhich appears to have advantages for in vivo imag-
ing [25–27]. Especially largermolecules containingmore than one bind-
ing epitope may lead to simultaneous multivalent binding [28,29].
However, the larger size of these constructs also increased uptake in
other organs (kidneys, muscle, control tumor, etc) that negatively im-
pact contrast was found. A comparable behavior was found for [68Ga]
FSC-(RGD)3, with higher tumor uptake in tumor but also higher reten-
tion in nontarget tissue. Comparing our trivalent FSC-RGD conjugate
with the recently described TRAP-(RGD)3 very similar properties were
found. 68Ga-TRAP-(RGD)3 showed a logD value of −3.9 revealing a
high hydrophilicity vs. −3.6 of [68Ga]FSC-(RGD)3 and an absolute
tumor uptake in vivo of 5.3 ± 1.3 versus 4.3 ± 0.6% ID/g for [68Ga]
FSC-(RGD)3) using the same tumor model [20], showing the suitability
of FSC based trimeric bioconjugates for preparation of 68Ga labeledmol-
ecules for efﬁcient targeting. Additionally, using appropriate protection
strategies for 1 or 2 amines of FSC also mono- and divalent constructs
should be chemically accessible; work towards this is currently ongoing
aswell as tests to label with other radiometals such as 89Zr, furthermore
optimization of radiolabeling protocols in particular towards moderate
radiolabeling conditions (pH, temperature) and testing the inﬂuenceof metals on radiolabelling. The presented data proved the concept of
using FSC based bioconjugates for 68Ga labeling as a promising tool for
the radiopharmaceutical scientist to develop targeted radiopharmaceu-
ticals for a variety of applications. Further studies in the evaluation of
this novel chelating scaffold are required to identify the true potential
of this development.
5. Conclusion
These initial data show that FSC can be used as bifunctional chelator
for synthesis of trimeric bioconjugates allowing 68Ga radiolabeling
within minutes at RT with high RCY at high speciﬁc activities. In vitro
tests revealed for [68Ga]FSC-(RGD)3 a strong hydrophilic character as
well as high stability towards all challenging solutions proved our hy-
pothesis. Moreover, [68Ga]FSC-(RGD)3 shows a high afﬁnity for the
αvβ3 integrin in the low nanomolar range as well as an elevated inter-
nalized activity for the αvβ3-positive M21 cells, whereas binding to
M21-L as well as after blocking is negligible receptor speciﬁcity. The
biodistribution study conﬁrmed the data found in vitro and additionally
revealed considerably improved tumor targeting in comparison to
[68Ga]NODAGA-RGD, supporting the concept of using FSC as basis for
development of novel targeted bioconjugates for PET applications.
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